UK bio-pharma - Innovation, re-invention and captial at risk
We all rely upon medical and scientific advances but the results and associated funding are inherently risky. The study examines the UK SME bio-pharma sector. It tracks AIM listed bio-pharmas to investigate return on investment and the level of capital at risk, considers the impact of the financial crisis on the sector, and seeks the views of senior executives of private and publicly quoted bio-pharmas and industry representatives.
Free digital download